Latest Updates from MiniFAB
Follow the link here to read the MiniFAB May Newsletter, our latest edition.
In it you'll find information about MiniFAB at AusMedtech and AACC 2013, Erol's CEO report, news on our milling capabilities and an update from our partners.
Five Tips for Successful Commercialisation of Lab-on-a-chip Diagnostics Mar 2013
Erol was caught on tape last year at the Lab-on-a-chip World Congress. Watch his presentation on ‘Five Tips for Successful Commercialisation of Lab-on-a-chip Diagnostics’. Be sure to turn the volume up.
MiniFAB Press Releases: February 2013 FEB 2013
Follow the link here to read the MiniFAB December Newsletter, our latest edition.
In it you'll find information about MiniFAB at SLAS 2013 where we'll be at Booth #426, our CEO report, information on bonding and an update from TearLab.
MiniFAB Press Releases: November 2012 NOV 2012
MiniFAB Press Releases: September 2012 SEP 2012
Click here to read the July Newsletter
In it you'll find information about MiniFAB at AACC 2012 where we'll be at Booth 2363, our CEO report, information on MiniFAB's approach to tackling on-cartridge reagent storage and Erol Harvey, MiniFAB's CEO and 2012 Victorian Manufacturing Hall of Fame's Enabling Technology Entrepreneur of the Year.
MiniFAB Press Releases: May 2012 MAY 2012
Click here to read the February Newsletter
In it you'll find information about MiniFAB at MD&M West 2012 where we'll be at Booth 828, our CEO report, information on TearLab’s Regulatory successes, and an update on the bionic eye project.
The TearLab Osmalarity test overcomes two key regulatory hurdles
Early this month TearLab announced that they had received communication from the FDA indicating that the Agency had approved its petition for a waiver under CLIA for their Osmalarity System. The good news kept coming last week with the Centers for Medicare and Medicaid Services (CMS) publishing instructions for the reimbursement rate for the TearLab Osmalarity test to be revised to $23.25 per eye, across all US States. "With both the CLIA Waiver and uneven reimbursement obstacles now overcome, we can look forward to the adoption curve of this groundbreaking test steeping significantly in 2012," said TearLab’s CEO, Elias Vamvakas.
"This is great news for TearLab. Having both the CLIA waiver and reimbursement will allow many more people to use the diagnostic system, and we at MiniFAB are looking forward to ramping up our production to meet the increase in demand," said MiniFAB's Manufacturing Manager, Bas Garst.
MiniFAB currently manufactures 70,000 nanofluidic test cards per month for TearLab.